Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome – positive acute lymphoblastic leukemia : results of the GRAAPH-2003 study
暂无分享,去创建一个
J. Cayuela | H. Dombret | E. Macintyre | X. Thomas | O. Reman | N. Ifrah | P. Rousselot | A. Buzyn | Martine | E. Delabesse | A. Pigneux | Y. Chalandon | J. Vernant | S. Maury | M. Vekemans | D. Réa | A. de Labarthe | F. Witz | M. Escoffre | V. Lhéritier | F. Huguet-Rigal | Arnaud | A. Labarthe | V. Lheritier | Pigneux | Escoffre | Yves | Chalandon
[1] M. Andreeff,et al. Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). , 2006 .
[2] G. Lenz,et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph^+ALL) , 2006 .
[3] H. Dombret,et al. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia , 2006, Leukemia.
[4] T. Naoe,et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Oldenburg,et al. Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib. , 2005 .
[6] Je-Hwan Lee,et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia , 2005, Leukemia.
[7] M. Baccarani,et al. Dramatic Improvement in CR Rate and CR Duration with Imatinib in Adult and Elderly Ph+ ALL Patients: Results of the GIMEMA Prospective Study LAL0201. , 2004 .
[8] J. Cayuela,et al. Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study. , 2004 .
[9] J. Esteve,et al. Treatment of Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) with Concurrent Chemotherapy and Imatinib Mesylate. , 2004 .
[10] H. Dombret,et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Cavé,et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.
[12] J. Bourhis,et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. , 2002, Blood.
[13] Sante Tura,et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.
[14] T. Lipp,et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. , 2002, Blood.
[15] J. Radich. Philadelphia chromosome-positive acute lymphocytic leukemia. , 2001, Hematology/oncology clinics of North America.
[16] D. Hoelzer,et al. Recent approaches in acute lymphoblastic leukemia in adults. , 2002, Critical reviews in oncology/hematology.
[17] M. Andreeff,et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.